---

---

United States
Securities and Exchange Commission
Washington, D.C. 20549


FORM 8-K


Current Report Pursuant to
Section 13 or 15(d) of the Securities Exchange Act of 1934


March 5, 2010
(Date of Report)


ULTRALIFE CORPORATION
(Exact name of registrant as specified in its charter)

(315) 332-7100
(Registrant’s telephone number, including area code)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

⃞ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

⃞ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

⃞ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

⃞ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

---

Item 5.02     Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 5, 2010, the Board of Directors (the “Board”) of Ultralife Corporation (the “Company”), on the recommendation of the Board’s Governance Committee, elected Thomas L. Saeli to the Board.  Mr. Saeli will stand for re-election to the Board with the Company’s other director nominees at the Company’s annual meeting of shareholders on June 8, 2010.  The Board expects to appoint Mr. Saeli to the Board’s Audit and Finance Committee and Strategy and Corporate Development Committee.

The Board has determined that Mr. Saeli is an independent director under NASDAQ governance standards.  There was no arrangement or understanding between Mr. Saeli and any other persons pursuant to which Mr. Saeli was selected as a director.  As of the date of this Current Report on Form 8-K, neither Mr. Saeli nor any of his immediate family members is a party, either directly or indirectly, to any transactions that would be required to be disclosed pursuant to Item 404(a) of Regulation S-K.

Mr. Saeli will be entitled to the same compensation as the other non-employee directors who serve on the Board, as previously described in the Company’s filings with the Securities and Exchange Commission.

A copy of the press release announcing Mr. Saeli’s election to the Board is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01     Financial Statements and Exhibits.

(d)  Exhibits.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Exhibit 99.1

Ultralife Corporation Names Thomas L. Saeli to Board of Directors

NEWARK, N.Y.--(BUSINESS WIRE)--March 11, 2010--Ultralife Corporation (NASDAQ: ULBI) announced that Thomas L. Saeli has joined its board of directors, effective March 5. Mr. Saeli, 53, brings 28 years’ experience in manufacturing, corporate development and finance.

Presently, Mr. Saeli is a consultant advising international corporate clients on matters involving business development strategies, consolidations, acquisitions and operations. Previously, from March 2006 until April 2009, he was chief executive officer of Noble International, Ltd., where he was also a member of Noble’s board of directors since 2002. Prior to joining Noble, from 1998 Mr. Saeli served as vice president of corporate development for Lear Corporation where he also served as vice president of mergers & acquisitions. Between 1989 and 1998 Mr. Saeli was a partner with Oxford Investment Group, a Michigan-based merchant banking firm, where he served in various senior operating roles of portfolio companies. From 1983 to 1988, Saeli served in several corporate finance positions with Pepsico, Inc. He earned a BA in Economics from Hamilton College and an MBA in Finance and Accounting from Columbia University Graduate School of Business.

John D. Kavazanjian, Ultralife’s president and chief executive officer, said, “Tom’s diverse background in international finance, business strategy and corporate development brings us a wealth of knowledge and experience. On behalf of the board of directors, we welcome Tom to Ultralife and look forward to having the benefit of his perspective and judgment in guiding our growth plans.”

About Ultralife Corporation

Ultralife Corporation, which began as a battery company, serves its markets with products and services ranging from portable and standby power solutions to communications and electronics systems. Through its engineering and collaborative approach to problem solving, Ultralife serves government, defense and commercial customers across the globe.

Ultralife’s family of brands includes: Ultralife Batteries, Stationary Power Services, RPS Power Systems, ABLE, McDowell Research, RedBlack Communications and AMTI. Ultralife’s operations are in North America, Europe and Asia. For more information, visit www.ultralifecorp.com.

This press release may contain forward-looking statements based on current expectations that involve a number of risks and uncertainties. The potential risks and uncertainties that could cause actual results to differ materially include: worsening global economic conditions, increased competitive environment and pricing pressures, and the possibility of intangible asset impairment charges that may be taken should management decide to retire one or more of the brands of acquired companies. The Company cautions investors not to place undue reliance on forward-looking statements, which reflect the Company’s analysis only as of today’s date. The Company undertakes no obligation to publicly update forward-looking statements to reflect subsequent events or circumstances. Further information on these factors and other factors that could affect Ultralife's financial results is included in Ultralife's Securities and Exchange Commission (SEC) filings, including the latest Annual Report on Form 10-K.

CONTACT:
Company Contact:
Ultralife Corporation
Julius Cirin, 315-332-7100
jcirin@ultralifecorp.com
or
Investor Relations Contact:
Lippert/Heilshorn & Associates, Inc.
Jody Burfening, 212-838-3777
jburfening@lhai.com